Fundraising FoxAM Pharma
4 known investors
Find your way into AM Pharma
Sign up to see every warm intro you have to AM Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AM Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
Investors · 4
How we know: Kurma Partners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Founder mafia
2 people who came through AM Pharma went on to found or lead other companies.
In the news
Frequently asked questions
- What does AM Pharma do?
- AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
- Who are AM Pharma's investors?
- AM Pharma's investors include Andera Partners, Kurma Partners, Ysios Capital, Forbion.